RNAC - Cartesian Therapeutics, Inc.

6.75
-0.220   -3.259%

Share volume: 118,888
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$6.97
-0.22
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 50%
Dept financing 42%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.32%
1 Month
11.02%
3 Months
-11.30%
6 Months
-23.73%
1 Year
-44.72%
2 Year
-67.90%
Key data
Stock price
$6.75
P/E Ratio 
N/A
DAY RANGE
$6.71 - $7.12
EPS 
-$5.01
52 WEEK RANGE
$5.60 - $15.57
52 WEEK CHANGE
-$44.72
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
26.509 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$181,298
AVERAGE 30 VOLUME 
$175,303
Company detail
CEO: Carsten Brunn
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.

Recent news